Valuation
- Market cap
- 375,468,000
- Revenue TTM
- $82,030,000
- Net income TTM
- $-65,780,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -80.19%
- Debt to equity
- 0.00
Trading
- Volume
- 744,800
- Avg volume
- 1,028,522
- Day's range
- $12.79 – $13.65
- Shares out
- 28,423,000
- Stochastic %K
- 12%
- Beta
- 2.48
- Analysts
- Strong Sell
- Price target
- $21.33
Company profile
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; an...
Show more
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 900 2660
- Website
- https://arcturusrx.com
- Address
- 10285 Science Center Drive, San Diego, United States
Latest news
No headlines yet.
